Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy

Abstract

Cystic fibrosis (CF) patients receive repeated courses of aminoglycoside therapy. These patients would consequently be expected to be more susceptible to cochleotoxicity, a recognized side effect with single courses of aminoglycoside therapy. The primary aim of this retrospective study was to establish the incidence and severity of auditory deficit in CF patients. Standard (0.25-to 8-kHz) and high-frequency (10-to 16-kHz) pure-tone audiometry was carried out in 70 CF patients, and the results were compared with the results from 91 control subjects. These subjects were further divided into pediatric and adult groups. Of 70 CF patients, 12 (1 pediatric) displayed hearing loss considered to be caused by repeated exposure to aminoglycosides. There was a nonlinear relationship between the courses of therapy received and the incidence of hearing loss. The severity of the loss did not appear to be related to the number of courses received. Assuming the risk of loss to be independent for each course, preliminary estimates of per course risk of hearing loss were less than 2%. Upon comparison with previous clinical studies and experimental work, these findings suggest that the incidence of cochleotoxicity in CF patients is considerably lower than would be expected, suggesting that the CF condition may confer protection against aminoglycoside cochleotoxicity.

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus

“…day -1 of tobramycin [102] and netilmicin [120] has been associated with symptoms of dizziness after the antibiotic infusion. However, surprisingly few side-effects have been reported in high dose aminoglycoside therapy [89,121,122]. Nevertheless, it is necessary to monitor ototoxicity and renal function and adjust the dosage interval accordingly, early in therapy [64].…”

Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations

“…Due to the chronicity of the lung infection, the severity of structural damage and the poorer penetration of drugs through thick mucosa, larger doses of antibiotics are required to treat CF PExs than in other groups of patients with lung infections. 1,3 Frequent and longer courses of IV treatment, particularly with aminoglycosides, has now been shown to be associated with renal impairment, 4,5 autotoxicity 6,7 as well as increased rate of antibiotic allergy. 8 In addition, extension of duration of IV antibiotic treatment is associated with added volume of work to patients, CF care workers and in incremental cost pressure of CF care.…”

Assessment of Nutrient Supplement to Reduce Gentamicin-Induced Ototoxicity

“…Drugs such as neomycin, tobramycin, kanamycin, streptomycin, amikacin, and gentamicin can affect hearing, balance, or both (Clark 1977;Xie et al 2011;Ahmed et al 2012). Despite potential ototoxicity and nephrotoxicity, aminoglycosides remain a drug of choice for use against gramnegative bacteria (see Xie et al 2011;Mulheran et al 2001;Hanberger et al 2013;Edson and Terrell 1999). Aminoglycoside antibiotics are also widely used to treat multidrug-resistant tuberculosis (MDR-TB).…”